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MaOBJECTIVES The aim of this study was to examine which component of drug-eluting stents (DES) plays a major role in
enhanced coronary vasoconstricting responses after DES implantation in pigs.
BACKGROUND Recent studies have reported unremitting angina due to vasomotion abnormalities even after suc-
cessful DES implantation. However, it remains to be elucidated which component of DES (metal stent, polymer coating,
or antiproliferative drug) is responsible for DES-induced coronary hyperconstricting responses.
METHODS We developed poly-DL-lactic acid and polycaprolactone (PDLLA-PCL) copolymer technology with higher
biocompatibility that is resorbed within 3 months. Four types of coronary stents were made: 1) a stent with polylactic acid
(PLA) polymer coating containing antiproliferative drug (P1þDþ); 2) a stent with PLA polymer coating alone without any
drug (P1þD–); 3) a stent with novel PDLLA-PCL polymer coating alone (P2þD–); and 4) a bare metal stent (P–D–). The
4 stents were randomly deployed in the left anterior descending and left circumﬂex coronary arteries in 12 pigs.
RESULTS After 1 month, coronary vasoconstriction by intracoronary serotonin was enhanced at P1þDþ and P1þD– stent
edges compared with P2þD– and P–D– stent edges and was prevented by a speciﬁc Rho-kinase (a central molecule of
coronary spasm) inhibitor, hydroxyfasudil. Immunostainings showed that inﬂammatory changes and Rho-kinase activa-
tion were signiﬁcantly enhanced at P1þDþ and P1þD– sites compared with P2þD– and P–D– sites. There were signiﬁcant
positive correlations between the extent of inﬂammation or Rho-kinase expression/activation and that of coronary
vasoconstriction.
CONCLUSIONS These results indicate the important roles of PLA polymer coating in DES-induced coronary vasocon-
stricting responses through inﬂammatory changes and Rho-kinase activation in pigs in vivo, which are ameliorated by
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ABBR EV I A T I ON S
AND ACRONYMS
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
PCI = percutaneous coronary
intervention
PDLLA-PCL = poly-DL-lactic
acid and polycaprolactone
PLA = polylactic acid
P1þDþ stent = stent with a
polylactic acid polymer and a
drug
P1þD stent = stent with a
polylactic acid polymer but
without a drug
P2þD stent = stent with a
poly-DL-lactic acid and
polycaprolactone copolymer
but without a drug
PD stent = stent without a
polymer or a drug
VSMC = vascular smooth
muscle cell
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282D rug-eluting stents (DES) have beenused most frequently in the ﬁeld ofinterventional cardiology world-
wide (1). Antiproliferative drug-elution of
DES, which is controlled for a ﬁxed period by
a polymer coating, has dramatically inhibited
neointimal formation and consequent risk of
in-stent restenosis (2). Despite these beneﬁ-
cial aspects, DES show no beneﬁcial prog-
nostic effect compared with conventional
bare metal stents (3). Notably, several large-
scale trials demonstrated that 30% of patients
with stable angina were still symptomatic 1
year after successful percutaneous coronary
intervention (PCI) (4) and that an initial
improvement of angina immediately after
revascularization was minimized at 3-year
follow-up compared with medical treatment
(5). Surprisingly, new or worsening angina
was also documented in patients who under-
went successful PCI with the most promising
product, everolimus-eluting stents (EES) (6).SEE PAGE 292Recently, impaired coronary vasomotion after DES im-
plantation has been reported (7–16) as a cause of new or
unremitting angina and a predictor of poor vascular
healing and subsequent stent thrombosis. Indeed, we
have demonstrated that DES-induced coronary
hyper-reactivity causes sudden cardiac arrest even af-
ter coronary revascularization (15). Thus, DES-induced
coronary hyperconstricting responses are an emerging
concern in the long-term safety of DES implantation.
We previously demonstrated that activation of a
Rho-kinase pathway, which we have identiﬁed as the
central molecular mechanism of coronary spasm
(16–19), is involved in the pathogenesis of DES-
induced coronary hyperconstricting responses in
animals (11–13) and humans (14) and that inﬂamma-
tory changes from DES subsequently cause Rho-
kinase activation (12–14). A DES consists of 3 major
components: a metal stent, a polymer coating, and an
antiproliferative drug (1). Although a polymer coating
could promote inﬂammatory changes (20,21), it re-
mains to be fully elucidated which component of a
DES plays a major role in DES-induced coronary
hyperconstricting responses.
To eliminate the unfavorable effects of DES, a
sophisticated biocompatible device is warranted. A
poly-DL-lactic acid and polycaprolactone (PDLLA-PCL)
copolymer matrix has been recently developed as an
innovative polymer technology with higher biocom-
patibility and is resorbed within 3 months (22,23),whereas the current polylactic acid (PLA) biocom-
patible polymers are resorbed for up to 6 months (24).
In the present study, we thus examined whether a
polymer coating is responsible for DES-induced cor-
onary hyperconstricting responses through Rho-
kinase activation in pigs in vivo and, if so, whether
novel PDLLA-PCL copolymer technology ameliorates
coronary hyperconstricting responses.
METHODS
All procedures were performed according to the pro-
tocols approved by the Institutional Committee for
Use of Laboratory Animals of Tohoku University
(2013MdA-059).
Detailed methods are provided in the Online
Methods and Online Figure 1.
RESULTS
STENT IMPLANTATION. The 4 different stents
(P1þDþ, P1þD, P2þD, and PD stents) were
randomly implanted in a total of 24 coronary seg-
ments (left anterior descending and left circumﬂex
arteries) of 12 miniature pigs (Figure 1). There was no
signiﬁcant difference in the stenting procedure,
including the number of major branch points at the
stent implantation sites, in the 4 groups (Online
Table 1).
CORONARY VASOMOTION AT 1 MONTH AFTER
STENT IMPLANTATION. At 1 month after stent im-
plantation, no signiﬁcant in-stent restenosis was
observed in the 4 groups (Figures 2A, 2D, 2G, and 2J).
Notably, coronary vasoconstricting responses to
intracoronary serotonin were enhanced at the prox-
imal and distal stent edges of the P1þDþ and
P1þD sites comparedwith the P2þD and PD stent
edges (Figures 2B, 2E, 2H, and 2K), and all of them were
abolished by pre-treatment with intracoronary
hydroxyfasudil, a selective Rho-kinase inhibitor
(Figures 2C, 2F, 2I, and 2L). Quantitative coronary
angiography showed that serotonin-induced coronary
vasoconstriction was signiﬁcantly enhanced at the
P1þDþ and P1þD stent edges compared with the
P2þD and PD stent edges (Figure 3). In contrast,
endothelium-dependent and -independent coronary
vasodilating responses to nitroglycerin and bradyki-
nin, regardless of the presence or absence of NG-mon-
omethyl-L-arginine, respectively, were all comparable
in the 4 groups (Online Figure 2).
HISTOMORPHOMETRY AT THE STENT IMPLANTATION
SITES AND THE STENT EDGES. At the stent implanta-
tion sites, the percentage of area stenosis tended
FIGURE 1 Study Protocol
The 4 different stents, P1þDþ, P1þD, P2þD, and PD (6 each), were randomly implanted in the LAD and LCX in 12 miniature pigs. At
1 month after stent implantation, animals underwent follow-up coronary angiography to assess coronary vasomotion in vivo and were then
euthanized for histological and immunohistological analyses of the inﬂammation and expression/activity of Rho-kinase. IC ¼ intracoronary;
LAD ¼ left anterior descending coronary artery; LCX ¼ left circumﬂex coronary artery; PD ¼ stent without a polymer or a drug; P1þDþ ¼
stent with a polylactic acid polymer and a drug; P1þD ¼ stent with a polylactic acid polymer but without a drug; P2þD stent with a poly-DL-
lactic acid and polycaprolactone copolymer but without a drug; PDLLA-PCL ¼ poly-DL-lactic acid and polycaprolactone; PLA ¼ polylactic acid.
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283to be lower at the P1þDþ sites compared with other 3
groups (Figures 4A to 4D, Online Table 2). Endothe-
lialization was almost complete at the 4 sites,
although slightly less at the P1þDþ sites comparedwith the other 3 sites (Online Table 2). At the stent
edges, no signiﬁcant difference in the histo-
morphometry was noted at the 4 stent sites (Online
Table 3).
FIGURE 2 Coronary Vasoconstricting Responses at the Stent Edges 1 Month After Stent Implantation in Pigs In Vivo
Representative left coronary angiograms after nitroglycerin (10 mg/kg, IC) (A, D, G, J), serotonin alone (100 mg/kg, IC) (B, E, H, K), and se-
rotonin after pre-treatment with hydroxyfasudil (a selective Rho-kinase inhibitor, 300 mg/kg IC) (C, F, I, L) 1 month after stent implantation. No
in-stent restenosis was noted in the 4 groups (A, D, G, J). Serotonin-induced coronary vasoconstriction was enhanced at the P1þDþ and P1þD
stent edges compared with the P2þD and PD stent edges (B, E, H, K) and was prevented with hydroxyfasudil (C, F, I, L). Each bar indicates
stent implantation sites; each arrow, stent edges. Abbreviations as in Figure 1.
Nishimiya et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6
Polymer and DES-Induced Coronary Hyperconstriction F E B R U A R Y 8 , 2 0 1 6 : 2 8 1 – 9 1
284INFLAMMATORY CHANGES IN THE STENT SITES AND
STENT EDGES. At the stent implantation sites, the
extent of inﬂammation was signiﬁcantly greater at
the P1þDþ and P1þD sites compared with the
P2þD and PD sites (Figures 4E to 4H, and 4M).
At the stent edges, more intense inﬂammatorychanges were noted in the coronary adventitia
compared with the intima or media (Figures 4I
to 4L). The extent of adventitial inﬂammation of
the stent edges was signiﬁcantly greater at the
P1þDþ and P1þD stent edges compared with
the P2þD and PD stent edges (Figure 4N).
FIGURE 3 Quantitative Coronary Angiography for Coronary Vasoconstricting
Responses 1 Month After Stent Implantation in Pigs In Vivo
Results of quantitative coronary angiography for coronary vasoconstricting response to
serotonin (10 and 100 mg/kg IC) before and after hydroxyfasudil (90 and 300 mg/kg
IC) 1 month after stent implantation. Coronary vasoconstricting responses to serotonin
were equally enhanced at the P1þDþ and P1þD stent edges compared with the
P2þD and PD stent edges. Those responses were all prevented by pre-treatment
with hydroxyfasudil. Results are expressed as mean  SEM. Abbreviations as in
Figure 1.
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285There were signiﬁcant positive correlations be-
tween the extent of the inﬂammation at the
stent implantation sites and the stent edges and
that of serotonin-induced coronary vasoconstriction
(Figures 4O and 4P).
RHO-KINASE ACTIVITY AT THE STENT EDGE.
Immunoreactivity of Rho-kinase expression (Rho-
kinase isoform b) and Rho-kinase activation (phos-
phorylated myosin phosphatase target subunit 1)
was enhanced at the coronary media of the P1þDþ
and P1þD stent edges compared with P2þD and
PD stent edges (Figures 5A to 5O). Importantly,
there were signiﬁcant positive correlations between
the extent of Rho-kinase expression/activation
and that of serotonin-induced coronary vasocon-
striction (Figures 5P to 5R). All parameters in-
cluding vasoconstriction to intracoronary serotonin,
inﬂammation, and Rho-kinase expression/activation
were not affected by the measurement position
(left anterior descending artery vs. left circum-
ﬂex artery, proximal site vs. distal site) (Online
Tables 4 and 5).
DISCUSSION
The major ﬁndings of the present study were that
coronary vasoconstricting responses were signiﬁ-
cantly enhanced at the P1þDþ and P1þD sites
compared with the PD site at 1 month after stent
implantation in pigs in vivo, which were dramatically
attenuated at P2þD site and those functional alter-
ations were signiﬁcantly associated with adventitial
inﬂammatory changes and Rho-kinase activation
(Figure 6).
ESSENTIAL ROLE OF A POLYMER COATING IN DES-
INDUCED CORONARY HYPERREACTIVITY. Widespread
use of DES has reduced the late lumen loss and
the rate of repeat revascularization (1,2). However,
an improvement in symptoms exhibited by suc-
cessful PCI is still limited. Emphasis should be
placed on the fact that 30% of stable angina
patients remained symptomatic 1 year after PCI
(4). Surprisingly, new or worsening angina was
also documented in the patients who underwent
PCI with EES (6). DES-induced coronary hyper-
constricting responses have currently been raised
as an important issue (7–16), resulting in new
or unremitting angina after DES implantation.
The high prevalence of coronary vasomotor abnor-
malities after PCI (w50%) was recently reported
(25). Impaired coronary vasomotion is associated
with increased cardiovascular risks (26). Indeed,
we recently reported on a patient who hadcardiac arrest associated with DES-induced coro-
nary hyperconstriction (15). Thus, more attention
should be paid to coronary hyperconstricting re-
sponses and resulting new or worsening angina
after successful PCI with DES.
A DES consists of 3 components: a metal stent, a
polymer coating, and an antiproliferative drug (1).
Although a polymer coating is necessary to permit
the drug release kinetics for a ﬁxed period, persis-
tent polymer residues in the coronary arterial
wall may be most responsible for the late-phase
FIGURE 4 Histological Analysis of Inﬂammatory Changes
Representative hematoxylin-eosin stainings of P1þDþ (A, E, I), P1þD (B, F, J), P2þD (C, G, K), and PD sites (D, H, L) 1 month after stent
implantation. Results of the semiquantitative analysis of the inﬂammatory changes in the stent implantation sites (M) and those in the
adventitia of the stent edges (N). The extent of inﬂammatory changes were signiﬁcantly greater in P1þDþ and P1þD sites compared with P2þD
 and PD stent edges (M, N). There were signiﬁcant positive correlations between the extent of inﬂammatory changes and that of
serotonin-induced coronary vasoconstriction (O, P). Results are expressed as mean  SEM (M, N). Abbreviations as in Figure 1.
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287inﬂammatory changes after DES implantation (20).
We have also demonstrated that sirolimus-eluting
stents enhance coronary vasoconstricting responses
compared with its platform bare metal stents
through inﬂammatory changes and subsequent Rho-
kinase activation in pigs and humans (11,14), sug-
gesting that the polymer coating or the eluting
drug, but not the metal stent, may be responsible
for the DES-induced coronary hyperconstricting
responses. In the present study, all of the cor-
onary stents were made of stainless steel with
120-mm-thick strut to precisely evaluate the effects
of a polymer coating and an eluting drug (Online
Figure 1). Although it has been hypothesized that
hyperreactivity to a polymer coating is involved in
the impairment of coronary vasoconstriction (7–13),
the inﬂuence of each stent component remains to
be fully elucidated. In the present study, we were
able to demonstrate that removal of both a PLA
polymer coating and an eluting drug from DES
system (PD) signiﬁcantly reduced coronary
hyperconstricting responses, whereas drug removal
alone (P1þD) was insufﬁcient. These results
thus provide the ﬁrst direct evidence that poly-
mer coating residues play a major role in the
coronary hyperconstricting responses after DES
implantation.
POTENTIAL BENEFITS OF PDLLA-PCL COPOLYMERS
ON DES-INDUCED CORONARY HYPERREACTIVITY.
Polymer blends of the PDLLA and the PCL matrix,
termed PDLLA-PCL copolymers, have actively been
used as biocompatible materials in clinical practice
(27). The PDLLA-PCL polymers have achieved
on higher biocompatibility and resorbed within 3
months (22,23) compared with the current PLA
polymers that are resorbed for 6 to 9 months (24).
Intriguingly, the stents with PDLLA-PCL copolymers
alone (P2þD) could dramatically ameliorate coro-
nary hyperconstricting responses compared with the
stents with PLA polymers alone (P1þD). In the
present study, an equivalent amount of polymers
was applied to both P1þD and P2þD stents using
the same abluminal-coating method (Figure 1)
(10,28). It is thus conceivable that the total amount
of polymer residues was much lower at the P2þD
sites compared with the P1þD sites at 1 month after
stent implantation. Although it was difﬁcult to
obtain detailed data on the degradation of each
polymer after P1þD and P2þD stent implantation
in pigs in vivo, the profound reduction of PDLLA-
PCL polymer residues at the P2þD sites may exert
inhibitory effects on coronary hyperconstricting
responses.INFLAMMATORY CHANGES AND RHO-KINASE ACTI-
VATION AFTER DES IMPLANTATION. In the present
study, histological examination demonstrated that
inﬂammatory changes at stent implantation sites
and stent edges were signiﬁcantly enhanced at the
P1þDþ and P1þD sites compared with the P2þD
and PD sites. Furthermore, there was a signiﬁ-
cant positive correlation between the extent of in-
ﬂammatory changes and that of serotonin-induced
coronary vasoconstriction. At the stent edges, more
intense inﬂammatory changes were noted in the
coronary adventitia compared with the intima or
media. We previously demonstrated that the stent
deployment initiates adventitial inﬂammatory
changes and that chronic adventitial inﬂammatory
changes are able to induce coronary spasm in pigs
in vivo (29,30). Taken together, the present results
indicate that inﬂammatory changes after DES im-
plantation are closely associated with the enhanced
coronary vasoconstricting responses in which poly-
mer residues may play a major role.
We have also previously demonstrated that Rho-
kinase expression/activation in vascular smooth
muscle cells plays a key role in the pathogenesis of
coronary spasm (16–19) and DES-induced coronary
hyperconstricting responses (11–13) in pigs. The
present results showed that Rho-kinase expression
and activation at the stent edges were enhanced,
especially in the medial vascular smooth muscle
cells of the P1þDþ and P1þD sites compared with
the P2þD and PD sites. Intriguingly, signiﬁcant
positive correlations were noted between the
extent of Rho-kinase expression/activation and that
of serotonin-induced coronary vasoconstriction.
Because inﬂammatory stimuli up-regulates Rho-
kinase expression/activity (31), it is highly possible
that the polymer coating itself enhances coro-
nary vasoconstricting responses through widespread
inﬂammation around the stents with resultant Rho-
kinase up-regulation and activation in the medial
vascular smooth muscle cells at the stent edges.
Moreover, small amount of polymer residues might
minimize inﬂammatory changes and resultant Rho-
kinase activation.
POTENTIAL THERAPY FOR THE INHIBITION OF DES-
ENHANCED VASOCONSTRICTION. PLA polymers
have a biocompatible property resorbed for 6 to 9
months and have already been applied to the
commercially available coronary stents (24). In the
present study, PLA polymers appeared to show
the mild but appreciable inﬂammatory changes
and enhance coronary vasoconstricting responses,
regardless of the PLA biocompatibility. A pig study
FIGURE 5 Immunohistological Analysis of Rho-kinase Expression and Activity
Representative immunostainings of P1þDþ, P1þD, P2þD, and PD edges for Rho-kinase b (ROCK1) (A to D), Rho-kinase a (ROCK 2)
(E to H) and phosphorylated myosin phosphatase target subunit 1 (pMYPT1) (a marker of Rho-kinase activity) (I to L) 1 month after stent
implantation. Results of the semiquantitative analysis for the extent of ROCK1 (M), ROCK2 (N), and pMYPT1 (O). Immunoreactivities for ROCK1
and pMYPT1 were signiﬁcantly enhanced in the medial layer of the P1þDþ and P1þD– edges compared with the P2þD– and P–D– edges
(M to O). There were signiﬁcant positive correlations between the extent of Rho-kinase expression/activation and that of serotonin-induced
coronary vasoconstriction (P to R). Results are expressed as mean  SEM (M to O). Abbreviations as in Figure 1.
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prominent around DES with PLA polymers in pigs
(28), supporting the present result. Notably, it wasrecently reported that unremitting angina attack
5 months after successful implantation of a bio-
resorbable vascular scaffold made of PLA polymers
FIGURE 6 Summary of the Present Study and Working Hypothesis
Coronary vasoconstricting responses were enhanced in the P1þDþ and P1þD sites
compared with PD sites 1 month after stent implantation in pigs in vivo,
suggesting that the polymer coating plays a major role in DES-induced coronary
hyperconstriction. PLA polymer coating initiates the mild but appreciable extent of
inﬂammatory changes in the stent sites and in the coronary adventitia of the stent
edges. At the stent edge, adventitial inﬂammation subsequently enhances Rho-kinase
expression and activity in the medial vascular smooth muscle cells. Finally,
DES-induced coronary hyperconstricting responses occur. In contrast, PDLLA-PCL
P2þD– dramatically ameliorates DES-induced coronary hyperconstricting responses
to its excellent biocompatible property. Abbreviations as in Figure 1.
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Thus, novel polymer technology with higher
biocompatibility is needed for an extreme reduc-
tion of hyperreactivity to polymer residues and
resultant unfavorable effects. On the basis of the
present results, the PDLLA-PCL copolymer coating
could be a promising biomaterial to ensure the
long-term safety of DES implantation. In fact, the
newly developed sirolimus-eluting stents with
PDLLA-PCL copolymers (Online Figure 1) showed
the 9-month short-term safety and efﬁcacy proﬁles
similar to those of EES (23) and preserved normal
coronary vasomotor responses to maximal atrial
pacing in humans (22). The long-term efﬁcacy of
this novel DES system should be examined in
future studies with a special reference to angina
due to DES-induced coronary hyperconstricting
responses.
We previously demonstrated that Rho-kinase
inhibitors are effective for coronary spasm in pa-
tients with vasospastic angina (16–19). In the pre-
sent study, hydroxyfasudil, a selective Rho-kinase
inhibitor, prevented serotonin-induced coronary
hyperconstriction in vivo, indicating that Rho-
kinase inhibitors could be another therapeutic
option for DES-induced coronary hyperconstricting
responses.
STUDY LIMITATIONS. Several limitations should be
mentioned for the present study. First, because
the present study was performed in normal pigs
without pre-existing coronary atherosclerotic le-
sions, caution should be used when extrapolating
the present ﬁndings to the clinical settings. How-
ever, the present study with normal pigs allowed
us to fully examine the foreign body reaction to
the biomaterials. Second, because we did not have
facilities to prepare the durable polymer-coated
stents, the roles of nonbioabsorbable durable
polymers applied to the most widely used EES
remain to be elucidated (Online Figure 1). However,
we were able to demonstrate the beneﬁcial effects
of novel biocompatible PDLLA-PCL copolymers
compared with the PLA polymers. Third, we used
serotonin to examine coronary vasoconstricting
responses, as previously described (11–13,16–18).
Although acetylcholine is most frequently used to
provoke coronary artery spasm in the clinical
setting, serotonin may better mimic spontaneous
coronary spasm in humans than acetylcholine (33).
Finally, the effects of endothelial shear stress on
the altered vascular responses after stent implanta-
tion remain to be examined in future studies.
However, for precise quantitative coronaryangiography analysis, the stents were gently
deployed across the major side branches in the
present study, predisposed to the development of
low endothelial shear stress and subsequent in-
ﬂammatory changes (34). Furthermore, all parame-
ters evaluated in the present study were not
affected by the measurement position (e.g., prox-
imal site vs. distal site). Because endothelial shear
stress is also driven by the thick-strut stents (35),
thinner strut stents (1,24) may be useful to address
this issue in future studies.
PERSPECTIVES
WHAT IS KNOWN? DES-induced coronary hyper-
constricting responses remain an important concern,
resulting in unremitting angina even after successful
revascularization.
WHAT IS NEW? The present study demonstrates for
the ﬁrst time that of the 3 components of a DES
(metal stent, polymer coating, and antiproliferative
drug), the polymer coating plays a major role in the
pathogenesis of DES-induced coronary hypercon-
stricting responses through inﬂammatory changes
and subsequent Rho-kinase activation in pigs in vivo,
which could be ameliorated by novel PDLLA-PCL
copolymer technology.
WHAT IS NEXT? Thus, a novel DES system using a
PDLLA-PCL copolymer could be a promising device to
reduce vasomotion abnormalities after DES
implantation.
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290CONCLUSIONS
The present study demonstrates the important
roles of a PLA polymer coating in DES-induced
coronary vasoconstricting responses through in-
ﬂammatory changes and Rho-kinase activation in
pigs in vivo, which are ameliorated by PDLLA-PCL
copolymers.
ACKNOWLEDGMENTS The authors thank Dr. S.
Yasuda and Dr. H. Ishibashi-Ueda for providing resin-
embedded histological sections, Y. Watanabe and A.
Nishihara for excellent technical assistance, Terumo
Corporation for providing the originally developed
coronary stents (P1þDþ, P1þD, P2þD, and PD
stents), and Asahi Kasei Pharma for providing
hydroxyfasudil.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Yasuharu Matsumoto, Department of Cardiovascular
Medicine, Tohoku University, Graduate School of Medi-
cine, Seiryo-machi, Aoba-ku 1-1, Sendai 980-8574, Japan.
E-mail: matsumoto@cardio.med.tohoku.ac.jp.RE F E RENCE S1. Stefanini GG, Holmes DR Jr. Drug-eluting
coronary-artery stents. N Engl J Med 2013;368:
254–65.
2. Morice MC, Serruys PW, Sousa, et al.
A randomized comparison of a sirolimus-eluting
stent with a standard stent for coronary revascu-
larization. N Engl J Med 2002;346:1773–80.
3. Spaulding C, Daemen J, Boersma E, Cutlip DE,
Serruys PW. A pooled analysis of data comparing
sirolimus-eluting stents with bare-metal stents.
N Engl J Med 2007;356:989–97.
4. Boden WE, O’Rourke RA, Teo KK, et al. Optimal
medical therapy with or without PCI for stable
coronary disease. N Engl J Med 2007;356:1503–16.
5. Pocock SJ, Henderson RA, Clayton T, et al.
Quality of life after coronary angiography or
continued medical treatment for angina: three-
year follow-up in the RITA-2 trial. Randomized
intervention treatment of angina. J Am Coll Car-
diol 2000;35:907–14.
6. Serruys PW, Chevalier B, Dudek D, et al.
A bioresorbable everolimus-eluting scaffold
versus a metallic everolimus-eluting stent for
ischaemic heart disease caused by de-novo native
coronary artery lesions (ABSORB II): an interim
1-year analysis of clinical and procedural second-
ary outcomes from a randomised controlled trial.
Lancet 2015;385:43–54.
7. Hamilos MI, Ostojic M, Beleslin B, et al. Differ-
ential effects of drug-eluting stents on local
endothelium-dependent coronary vasomotion.
J Am Coll Cardiol 2008;51:2123–9.
8. Pendyala LK, Yin X, Li J, Chen JP, Chronos N,
Hou D. The ﬁrst-generation drug-eluting stentsand coronary endothelial dysfunction. J Am Coll
Cardiol Intv 2009;2:1169–77.
9. Mitsutake Y, Ueno T, Yokoyama S, et al. Coro-
nary endothelial dysfunction distal to stent of
ﬁrst-generation drug-eluting stents. J Am Coll
Cardiol Intv 2012;5:966–73.
10. PendyalaLK,MatsumotoD,ShinkeT,etal.Nobori
stent shows less vascular inﬂammation and early
recovery of endothelial function compared with
Cypher stent. J Am Coll Cardiol Intv 2012;5:436–44.
11. Shiroto T, Yasuda S, Tsuburaya R, et al. Role of
Rho-kinase in the pathogenesis of coronary
hyperconstricting responses induced by drug-
eluting stents in pigs in vivo. J Am Coll Cardiol
2009;54:2321–9.
12. Tsuburaya R, Yasuda S, Shiroto T, et al. Long-
term treatment with nifedipine suppresses
coronary hyperconstricting responses and inﬂam-
matory changes induced by paclitaxel-eluting
stent in pigs in vivo: possible involvement of
Rho-kinase pathway. Eur Heart J 2012;33:791–9.
13. Nishimiya K, Matsumoto Y, Takahashi J, et al.
Association of adventitial vasa vasorum and
inﬂammation with coronary hyperconstriction af-
ter drug-eluting stent implantation in pigs in vivo.
Circ J 2015;79:1787–98.
14. Aizawa K, Yasuda S, Takahashi J, et al.
Involvement of rho-kinase activation in the
pathogenesis of coronary hyperconstricting re-
sponses induced by drug-eluting stents in pa-
tients with coronary artery disease. Circ J 2012;
76:2552–60.
15. Takeda M, Shiba N, Takahashi J, Shimokawa H.
A case report of very late stent thrombosis withperi-stent coronary artery aneurysm and stent-
related coronary vasospasm. Cardiovasc Interv
Ther 2013;28:272–8.
16. Shimokawa H. 2014 Williams Harvey Lecture:
Importance of coronary vasomotion
abnormalities-from bench to bedside. Eur Heart J
2014;35:3180–93.
17. Kandabashi T, Shimokawa H, Miyata K, et al.
Inhibition of myosin phosphatase by upregulated
rho-kinase plays a key role for coronary artery
spasm in a porcine model with interleukin-1b.
Circulation 2000;101:1319–23.
18. Shimokawa H, Takeshita A. Rho-kinase is an
important therapeutic target in cardiovascular
medicine. Arterioscler Thromb Vasc Biol 2005;25:
1767–75.
19. Masumoto A, Mohri M, Shimokawa H,
Urakami L, Usui M, Takeshita A. Suppression of
coronary artery spasm by the Rho-kinase inhibitor
fasudil in patients with vasospastic angina. Circu-
lation 2002;105:1545–7.
20. Virmani R, Guagliumi G, Farb A, et al.
Localized hypersensitivity and late coronary
thrombosis secondary to a sirolimus-eluting
stent: should we be cautious? Circulation 2004;
109:701–5.
21. van der Giessen WJ, Lincoff AM, Schwartz RS,
et al. Marked inﬂammatory sequelae to implan-
tation of biodegradable and nonbiodegradable
polymers in porcine coronary arteries. Circulation
1996;94:1690–7.
22. Stojkovic S, Neskovic AN, Mehmedbegovic Z,
et al. Reduced sirolimus systemic exposure and
improved bioresorbable polymer properties: new
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6 Nishimiya et al.
F E B R U A R Y 8 , 2 0 1 6 : 2 8 1 – 9 1 Polymer and DES-Induced Coronary Hyperconstriction
291allies for the treatment of patients with coronary
artery disease. Fundam Clin Pharmacol 2015;29:
95–105.
23. Saito S, Valdes-Chavarri M, Richardt G, et al.
A randomized, prospective, intercontinental eval-
uation of a bioresorbable polymer sirolimus-
eluting coronary stent system: the CENTURY II
(Clinical Evaluation of New Terumo Drug-Eluting
Coronary Stent System in the Treatment of Pa-
tients with Coronary Artery Disease). Eur Heart J
2014;35:2021–31.
24. Garg S, Bourantas C, Serruys PW. New con-
cepts in the design of drug-eluting coronary
stents. Nat Rev Cardiol 2013;10:248–60.
25. Ong P, Athanasiadis A, Perne A, et al. Coronary
vasomotor abnormalities in patients with stable
angina after successful stent implantation but
without in-stent restenosis. Clin Res Cardiol 2014;
103:11–9.
26. Maseri A, Beltrame JF, Shimokawa H. Role of
coronary vasoconstriction in ischemic heart dis-
ease and search for novel therapeutic targets. Circ
J 2009;73:394–403.
27. Todo M, Park SD, Takayama T, et al. Fracture
micromechanisms of bioabsorbable PLLA/PCLpolymer blends. Eng Fract Mech 2007;74:
1872–83.
28. Tada N, Virmani R, Grant G, et al. Polymer-free
biolimus A9-coated stent demonstrates more sus-
tained intimal inhibition, improved healing, and
reduced inﬂammation compared with a polymer-
coated sirolimus-eluting cypher stent in a porcine
model. Circ Cardiovasc Interv 2010;3:174–83.
29. Matsumoto Y, Uwatoku T, Shimokawa H, et al.
Long-term inhibition of Rho-kinase suppresses
neointimal formation after stent implantation in
porcine coronary arteries: involvement of multiple
mechanisms. Arterioscler Thromb Vasc Biol 2004;
24:181–6.
30. Shimokawa H, Ito A, Fukumoto Y, et al.
Chronic treatment with interleukin-1b induces
coronary intimal lesions and vasospastic responses
in pigs in vivo. The role of platelet-derived growth
factor. J Clin Invest 1996;97:769–76.
31. Hiroki J, Shimokawa H, Higashi M, et al.
Inﬂammatory stimuli upregulate Rho-kinase in
human coronary vascular smooth muscle cells.
J Mol Cell Cardiol 2004;37:537–46.
32. Lindemann H, Sechtem U, Ong P, et al.
Recurrent angina due to epicardial coronary spasmafter successful bioresorbable vascular scaffold
implantation. Circ J 2015;79:1853–4.
33. Kanazawa K, Suematsu M, Ishida T, et al.
Disparity between serotonin- and acetylcholine-
provoked coronary artery spasm. Clin Cardiol
1997;20:146–52.
34. Farb A, Burke AP, Kolodgie FD, Virmani R.
Effect of endothelial shear stress on the pro-
gression of coronary artery disease, vascular
remodeling, and in-stent restenosis in humans.
Circulation 2003;108:1701–6.
35. Katrati A, Mehilli J, Dirschinger J, et al. Intra-
coronary stenting and angiographic results: strut
thickness effect on restenosis outcome (ISAR-
STEREO) trial. Circulation 2001;103:2816–21.KEY WORDS inﬂammation, polymers,
stents, Rho-kinase
APPENDIX For an expanded Methods section
and supplemental references, tables, and
ﬁgures, please see the online version of this
article.
